Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-212687
Abstract: Objectives To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA). Methods Adults (n=996) with active PsA were randomised 2:2:2:3… read more here.
Keywords: psoriatic arthritis; week; 150 without; radiographic progression ... See more keywords
Are the loading dose treatment groups superior to the 150 mg without loading dose group in the secukinumab FUTURE 5 study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-213770
Abstract: I read with great interest the article by Mease et al 1 because equivalence in efficacy with lesser secukinumab total doses could be less expensive to payers and more safe and comfortable to patients. However, I am… read more here.
Keywords: loading dose; 150 without; treatment groups; superior 150 ... See more keywords